human sars-cov-2 neutralizing antibody cor-101 demonstrates high efficacy in a covid-19 animal model and is ready to be used in clinical studies to treat covid-19 patients.
human sars-cov-2 neutralizing antibody cor-101 demonstrates high efficacy in a covid-19 animal model and is ready to be used in clinical studies to treat covid-19 patients.
the crystal structure of cor-101 in complex with sars-cov-2-rbd was solved at 2.0 a resolution showing that the antibody binds at the same region as the human coronavirus receptor ace2 to sars-cov-2-rbd.", "the best antibody currently is in production to be clinically tested soon as immunotherapy to treat acute covid-19.", "a large set of more than 750 human monoclonal antibodies recognizing sars-cov2 spike (s) protein isolated by antibody phage display from human antibody libraries from healthy donors and convalescent covid-19 patients underwent a fast track development process to identify lead molecule with optimal drug features for a passive vaccine.", 


































"here we report the isolation of two specific human monoclonal antibodies (termed ca1 and cb6) from a patient convalescing from covid-19.")